Skip to main content

Market Overview

FDA Approves Medtronic's Embolization Device For Stopping Brain Aneurysms

FDA Approves Medtronic's Embolization Device For Stopping Brain Aneurysms


  • The FDA has approved Medtronic plc’s (NYSE: MDT) Pipeline Flex Embolization Device with Shield Technology, a chemically bonded, synthetic coating that helps camouflage the metal implant from blood cells and hides it from the body’s typical responses to an invading object.
  • The company celebrated the 10th anniversary of the implant when it was first introduced in the U.S, designed to divert blood flow away from a brain aneurysm and prevent its rupture.
  • The coating also makes the device slipperier, allowing it to slide more easily through curving vasculature during placement and deploy with less force than earlier generations.
  • Medtronic describes the latest version as the first surface-modified implant to show reductions in thrombogenicity, or the tendency for a material to create blood clots. The device’s first patient underwent treatment at NYU Langone Health.
  • In 2019, the company received approval of an expanded indication from the FDA for its Pipeline Flex embolization device for patients with smaller aneurysms found deeper in the brain.
  • Price Action: MDT shares are up 1.92% at $130.74 in market trading hours on the last check Wednesday.


Related content: Benzinga's Full FDA Calendar






Related Articles (MDT)

View Comments and Join the Discussion!

Posted-In: Aneurysm BriefsBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at